Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description- A detailed description of the company’s operations and business divisions.
  • Corporate strategy- Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis- A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history- Progression of key events associated with the company.
  • Major products and services- A list of major products, services and brands of the company.
  • Key competitors- A list of key competitors to the company.
  • Key employees- A list of the key executives of the company.
  • Executive biographies- A brief summary of the executives’ employment history.
  • Key operational heads- A list of personnel heading key departments/functions.
  • Important locations and subsidiaries- A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities- A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years- The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods- The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, and zika viral infectious. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Jan 16,2019 VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
Jan 07,2019 VALNEVA announces its intention to delist from the vienna stock exchange
Nov 08,2018 VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with €50m financing
Oct 16,2018 VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Valneva SE - Key Facts
Valneva SE - Key Employees
Valneva SE - Key Employee Biographies
Valneva SE - Major Products and Services
Valneva SE - History
Valneva SE - Company Statement
Valneva SE - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2- Company Analysis
Company Overview
Valneva SE - Business Description
Product Category: Dukoral
Overview
Performance
Product Category: Ixiaro/Jespect
Overview
Performance
Key Stats
Product Category: Revenues from Collaborations, Licensing and Services
Performance
R&D Overview
Valneva SE - Corporate Strategy
Valneva SE - SWOT Analysis
SWOT Analysis - Overview
Valneva SE - Strengths
Valneva SE - Weaknesses
Valneva SE - Opportunities
Valneva SE - Threats
Valneva SE - Key Competitors
Section 3- Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4- Company’s Lifesciences Financial Deals and Alliances
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Valneva SE, Recent Deals Summary
Section 5- Company’s Recent Developments
Jan 16, 2019: VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
Jan 07, 2019: VALNEVA announces its intention to delist from the vienna stock exchange
Nov 08, 2018: VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with €50m financing
Oct 16, 2018: VALNEVA Announces Progress of Chikungunya Vaccine Candidate
Oct 05, 2018: VALNEVA Announces FDA Approval of Accelerated IXIARO® Vaccination Schedule
Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan
Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1
Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members
Jun 13, 2018: Valneva: Protecting unborn babies from Zika
May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs
Section 6- Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Valneva SE, Key Facts
Valneva SE, Key Employees
Valneva SE, Key Employee Biographies
Valneva SE, Major Products and Services
Valneva SE, History
Valneva SE, Other Locations
Valneva SE, Subsidiaries
Valneva SE, Key Competitors
Valneva SE, Ratios based on current share price
Valneva SE, Annual Ratios
Valneva SE, Annual Ratios (Cont...1)
Valneva SE, Interim Ratios
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Valneva SE, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Valneva SE, Performance Chart (2013 - 2017)
Valneva SE, Ratio Charts
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook